This test uses bi-directional sequencing of hotspot regions in BTK and PLC-gamma-2 genes, including the BTK mutation C481S and key PLC-gamma-2 mutations: R665W, S707, and L845F.
BTK Inhibitor Acquired Resistance Panel
- Molecular
Specimen Requirements
Bone Marrow Aspirate: 2 mL in EDTA tube.
Peripheral Blood: 5 mL in EDTA tube.
Note: Test is DNA-based. Please select Extract & Hold - DNA if specimen hold service is desired.
Storage and Transportation
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. For fresh samples: refrigerate before shipping and ship same day as drawn whenever possible. Do not freeze. Please select extract & hold - DNA if specimen hold service is desired.
CPT Code(s)*
81233, 81320
Turnaround time
10 Days
Level of Service
- Global
Integrations
Request electronic integrations →
New York Approved: No
Clinical Significance
This panel detects mutations in BTK and PLC-gamma-2 which are associated with acquired ibrutinib resistance in certain B-cell neoplasms. This panel is appropriate for patients with B-cell neoplasms who have relapsed and/or show acquired (secondary) resistance after an initial response to BTK (Bruton tyrosine kinase) inhibitors.
*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.
Biomarkers
DNA Sequencing
| SNVs + Indels | |||||
|---|---|---|---|---|---|
| BTK | PLCG2 | ||||
Last Updated: March 06, 2026